Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 79Carboplatin 64Bevacizumab 33liposomal doxorubicin 29Topotecan 28Gemcitabine 25Cisplatin 19olaparib 18Drug Therapy 12Doxorubicin 12Taxes 11niraparib 9Docetaxel 6CP protocol 6Trabectedin 5Hyperthermic Intraperitoneal Chemotherapy 5Etoposide 5Cyclophosphamide 51-dodecylpyridoxal 5rucaparib 4pembrolizumab 4avelumab 4atezolizumab 4Immunoglobulin G 4Ifosfamide 4Disulfides 4Dexamethasone 4Chemotherapy, Adjuvant 4trebananib 3fluzoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Ovarian Neoplasms × trebananib × Clear all
NCT01281254 2017-12-02

TRINOVA-2

Amgen

Phase 3 Terminated
223 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01493505 2017-02-23

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Amgen

Phase 3 Terminated
1,015 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01204749 2016-12-15

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Amgen

Phase 3 Completed
919 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡